Cyclacel Pharmaceuticals logo

Cyclacel PharmaceuticalsNASDAQ: CYCC

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

16 March 2004

Next earnings report:

19 March 2025

Last dividends:

N/A

Next dividends:

N/A
$2.35 M
-94%vs. 3y high
7%vs. sector
-vs. 3y high
-vs. sector
-137%vs. 3y high
7%vs. sector
-33%vs. 3y high
88%vs. sector

Price

after hours | Tue, 19 Nov 2024 23:30:06 GMT
$0.37+$0.02(+4.91%)

Dividend

No data over the past 3 years
$10.00 K$10.00 K
$10.00 K-$1.96 M

Analysts recommendations

Institutional Ownership

CYCC Latest News

Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q3 Loss
zacks.com12 November 2024 Sentiment: POSITIVE

Cyclacel Pharmaceuticals, Inc. (CYCC) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $7.35 per share a year ago.

Cyclacel Pharmaceuticals, Inc. (CYCC) Q2 2024 Earnings Call Transcript
seekingalpha.com14 August 2024 Sentiment: POSITIVE

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC ) Q2 2024 Earnings Call Transcript August 14, 2024 4:30 PM ET Company Participants Grace Kim - IR Spiro Rombotis - President and CEO Brian Schwartz - CMO Paul McBarron - EVP, Finance & COO Conference Call Participants Ahu Demir - Ladenburg Thalmann Grace Kim Good afternoon, everyone. And thank you for joining today's conference call to discuss Cyclacel's financial results and business highlights for the second quarter ended June 30, 2024.

Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q2 Loss, Misses Revenue Estimates
zacks.com14 August 2024 Sentiment: NEUTRAL

Cyclacel Pharmaceuticals, Inc. (CYCC) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $6.60 per share a year ago.

Cyclacel Pharmaceuticals (CYCC) Upgraded to Strong Buy: Here's What You Should Know
zacks.com25 July 2024 Sentiment: POSITIVE

Cyclacel Pharmaceuticals (CYCC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

All You Need to Know About Cyclacel Pharmaceuticals (CYCC) Rating Upgrade to Buy
zacks.com06 June 2024 Sentiment: POSITIVE

Cyclacel Pharmaceuticals (CYCC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Cyclacel's Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting
globenewswire.com04 June 2024 Sentiment: POSITIVE

- Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific  mechanism of action -

Cyclacel Pharmaceuticals, Inc. (CYCC) Q1 2024 Earnings Call Transcript
Seeking Alpha14 May 2024 Sentiment: NEUTRAL

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) held its Q1 2024 Earnings Call on May 14, 2024 at 4:30 PM ET. Present on the call were Grace Kim - Investor Relations, Spiro Rombotis - President and CEO, Brian Schwartz - Chief Medical Officer, and Paul McBarron - Executive Vice President of Finance & COO. The conference call began with a welcome from the operator and all participants were in a listen-only mode.

Why Is Cyclacel Pharmaceuticals (CYCC) Stock Up 46% Today?
InvestorPlace30 April 2024 Sentiment: POSITIVE

Cyclacel Pharmaceuticals' stock is surging today following the company's decision to withdraw a public offering that was initially filed in March, as reported in an SEC filing.

Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer
GlobeNewsWire01 April 2024 Sentiment: POSITIVE

- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid tumors and lymphoma -

Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2023 Earnings Call Transcript
Seeking Alpha19 March 2024 Sentiment: POSITIVE

Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2023 Earnings Call Transcript

What type of business is Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

What sector is Cyclacel Pharmaceuticals in?

Cyclacel Pharmaceuticals is in the Healthcare sector

What industry is Cyclacel Pharmaceuticals in?

Cyclacel Pharmaceuticals is in the Biotechnology industry

What country is Cyclacel Pharmaceuticals from?

Cyclacel Pharmaceuticals is headquartered in United States

When did Cyclacel Pharmaceuticals go public?

Cyclacel Pharmaceuticals initial public offering (IPO) was on 16 March 2004

What is Cyclacel Pharmaceuticals website?

https://www.cyclacel.com

Is Cyclacel Pharmaceuticals in the S&P 500?

No, Cyclacel Pharmaceuticals is not included in the S&P 500 index

Is Cyclacel Pharmaceuticals in the NASDAQ 100?

No, Cyclacel Pharmaceuticals is not included in the NASDAQ 100 index

Is Cyclacel Pharmaceuticals in the Dow Jones?

No, Cyclacel Pharmaceuticals is not included in the Dow Jones index

When was Cyclacel Pharmaceuticals the previous earnings report?

No data

When does Cyclacel Pharmaceuticals earnings report?

The next expected earnings date for Cyclacel Pharmaceuticals is 19 March 2025